12:00 AM
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Gammagard Liquid 10% regulatory update

Baxter submitted an sBLA to FDA for Gammagard Liquid 10% to treat multifocal motor neuropathy (MMN). The IgG antibodies plasma-based therapy is already approved in the...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >